Clinical trials

Clear cell renal cell carcinoma is the most common type of kidney cancer. Although new treatments such as immune checkpoint inhibitors and targeted therapies have improved outcomes for many patients, some patients with advanced disease may still experience disease progression and require new treatment approaches. This study evaluates the safety, feasibility, and preliminary effectiveness of a novel cell therapy called CA9-targeted chimeric antigen receptor macrophage (CAR-M) therapy in patients with unresectable or metastatic clear cell renal cell carcinoma. CA9 is a protein that is highly expressed on many clear cell renal cell carcinoma cells and can be recognized by CAR-M cells. In this study, patients will receive a local injection of CM-BA-9, a CA9-targeted CAR-M cell product, into selected tumor lesions. The study will primarily assess treatment safety and tolerability, while also exploring whether this therapy can control tumor growth. The information collected in this study may help researchers better understand the potential role of CAR-M therapy in the treatment of advanced clear cell renal cell carcinoma.